Updated expert consensus statement on transcatheter left atrial appendage closure released

NewsGuard 100/100 Score

Today, the Society for Cardiovascular Angiography & Interventions (SCAI) and the Heart Rhythm Society (HRS) released an updated expert consensus statement on transcatheter left atrial appendage closure (LAAC). SCAI and HRS prioritized the development of an updated consensus statement to provide recommendations on contemporary, evidence-based best practices for transcatheter LAAC focusing on endovascular devices.

Left atrial appendage closure is a minimally invasive procedure that is used to reduce the risk of stroke associated with atrial fibrillation. Atrial fibrillation is a common form of arrhythmia, a condition in which the heart beats out of rhythm. Atrial fibrillation (AF) is associated with a 4- to 5-fold increased risk of ischemic stroke and accounts for 25% of the 700,000 cerebrovascular accidents that occur in the United States annually.

Summary of recommendations:

1. Transcatheter LAAC is appropriate for patients with nonvalvular atrial fibrillation with high thromboembolic risk who are not suited for long-term oral anticoagulation and who have adequate life expectancy.

2.1. Physicians performing LAAC should have prior experience, including ≥50 prior left-sided ablations or structural procedures and ≥25 transseptal punctures (TSPs). Interventional imaging physicians should have experience in guiding ≥25 TSPs before supporting any LAAC procedures independently.

2.2. For maintenance of skills, implanting physicians should perform ≥25 TSPs and >12 LAACs over each 2-year period.

2.3. New programs and implanting physicians early in their LAAC experience should have on-site cardiovascular surgery backup.

3. Baseline imaging with transesophageal echocardiography (TEE) or cardiac computed tomography is recommended before LAAC.

4. Intraprocedural imaging guidance with TEE or intracardiac echocardiography is recommended.

5. Technical aspects of the procedure, including venous access, anticoagulation, transseptal puncture, delivery sheath selection and placement, left atrial pressure measurement, and device deployment, should be performed in accordance with the labeling of each specific LAAC device.

6. Operators need to be familiar with avoidance, recognition, and management of procedural complications associated with LAAC.

7. Predischarge imaging should be performed with 2-dimensional transthoracic echocardiography to rule out pericardial effusion and device embolization.

8. Device-related thrombus should be treated with anticoagulation.

9. Routine closure of iatrogenic atrial septal defects associated with LAAC should not be performed.

10. The clinical impact and management of peridevice leaks are not fully understood, and all efforts should be made to minimize such leaks at the time of implantation.

11. Patients should be prescribed antithrombotic therapy with warfarin, direct oral anticoagulants, or dual antiplatelet therapy after LAAC according to the studied regimen and instructions for use for each specific device and tailored to the bleeding risks of each patient.

12. TEE or cardiac computed tomography is recommended at 45 to 90 days after LAAC for device surveillance to assess for peridevice leak and device-related thrombus.

13. Combined procedures with LAAC (e.g., structural interventions, pulmonary vein isolation) are not routinely recommended, as data are pending from ongoing randomized controlled trials.

This consensus statement demonstrates the evolvement of LAAC treatment since our first statements that were issued in 2015 and 2016. Since then, the results from several important clinical trials and registries, as well as other technological and clinical advancements have evolved and changed the way we look at operator requirements, patient selection, and shared decision making, which explains the need for this updated guidance."

Jacqueline Saw, MD, FSCAI, chair of the writing group and an interventional cardiologist at Vancouver General Hospital and St Paul's Hospital, Clinical Professor of Medicine at UBC, and Program Director of the VGH Interventional Cardiology Fellowship Program

This statement has been developed according to the SCAI Publications Committee policies for writing group composition, disclosure, and management of relationships with industry, internal and external review, and organizational approval. The writing group has been organized to ensure diversity of perspectives and demographic characteristics, multistakeholder representation, and appropriate balance of relationships with industry. Relevant financial disclosures are available in the manuscript.

The American College for Cardiology and the Society of Cardiovascular Computed Tomography endorsed the statement.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Ten doctors on FDA panel reviewing Abbott heart device had financial ties with company